About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Drug Therapies May Effectively Treat Subgroup of Schizophrenia Patients

by Reshma Anand on December 9, 2015 at 2:06 PM
Font : A-A+

New Drug Therapies May Effectively Treat Subgroup of Schizophrenia Patients

As the disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia, the glutamate pathway has become the target of a number of new drug therapies, revealed a new study. The findings were published in the journal Biological Psychiatry and it suggests that at least one of these drugs may be an effective treatment for individuals in the early course of the illness.

Re-analyzed data from inconclusive clinical trials of a compound called pomaglumetad methionil suggest that a more targeted population of subjects--patients who are early-in-disease or patients who have not already been exposed to other antipsychotic medications--may have produced a statistically significant response.

Advertisement


The authors of the current study hypothesize that these previous trials may have inadvertently selected subjects who would be nonresponsive to the medication and conclude that future efficacy trials may require the identification of subgroups of patient populations.

"The complex pathophysiology of schizophrenia and resultant patient heterogeneity present significant challenges to developing new and effective therapies for this disorder. Receptor selective compounds such as pomaglumetad may target specific sites that mediate disease in some but not all patients. Our tentative, though testable, findings may provide a direction for the development of personalized treatments for a patient subgroup whose illness is associated with a dysregulation of brain glutamate function," said corresponding author Dr. Bruce Kinon of Lundbeck LLC.
Advertisement

"As we develop drugs that work by targeting the primary brain pathology in schizophrenia, it is likely that the differences between patients are going to play a bigger role in determining optimal treatment," commented Dr. John Krystal, Editor of Biological Psychiatry. "Kinon and his colleagues present interesting data suggesting that although pomaglumetad methionil does not work for all patients, it may be helpful for patients early in their course of illness or who have not had extensive prior treatment with a second generation antipsychotic medication or other serotonin-2 receptor antagonist."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Schizophrenia Clinical Trials - Different Phases of the trial Signature Drug Toxicity Mental Health - Neurosis vs Psychosis Schizoaffective Disorder Mind-wandering Paranoia Anosognosia Antipsychotic Medications 

Most Popular on Medindia

Iron Intake Calculator Blood Donation - Recipients Blood Pressure Calculator Diaphragmatic Hernia Drug Interaction Checker Post-Nasal Drip A-Z Drug Brands in India Color Blindness Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Accident and Trauma Care
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

New Drug Therapies May Effectively Treat Subgroup of Schizophrenia Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests